3 news items
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
MREO
3 Apr 24
a Phase 1b/2 basket study evaluating its safety and efficacy in combination with an anti-PD-1 in a range of tumor types including three rare tumors
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
MREO
27 Mar 24
oncology product candidates in clinical development. Etigilimab (anti-TIGIT) has completed a Phase 1b/2 basket study evaluating its safety
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
MREO
5 Mar 24
candidates in clinical development. Etigilimab (anti-TIGIT) has completed a Phase 1b/2 basket study evaluating its safety and efficacy in combination
- Prev
- 1
- Next